ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Laurus Labs announced the NCLT has issued an order regarding its Composite Scheme of Arrangement. The court directed notices be served for the upcoming September hearing.
Laurus Labs Ltd has approved the voluntary closure of its non-material German subsidiary, Laurus Generics GmbH. The subsidiary reported nil turnover for FY 2025-26 and its closure is expected to have no material impact on the company's consolidated financials.
Laurus Labs approved an additional investment of approximately ₹107.80 Crore (EURO 9.8 million) in its joint venture, KRKA Pharma Private Limited. The funds will support KRKA's capital expenditure for setting up a manufacturing facility. The company's shareholding in the JV will remain unchanged at 49%.
Laurus Labs approved an investment of approximately ₹107.80 Crore (EURO 9.8 million) in its joint venture, KRKA Pharma Private Limited. The funds will support the setup of a manufacturing facility. Additionally, the company announced two independent director appointments and the voluntary closure of its step-down German subsidiary.
Laurus Labs announced that unsecured creditors of its subsidiaries, Laurus Synthesis and Sriam Labs, have approved a Composite Scheme of Arrangement. This approval marks a significant milestone in the restructuring process. The scheme remains subject to final approval from the NCLT and other regulatory authorities.